Dr. Brian Wood describes the clinical indications, administration, and mechanism of action of the entry inhibitor ibalizumab, a unique antiretroviral drug generally reserved for salvage therapy. For more videos visit the National HIV Curriculum website: [ Ссылка ].
0:00 Intro
0:35 Basics
1:53 Mechanism of Action
3:12 Humanized Monoclonal Antibody
3:34 Host Cell CD4 Receptor
4:27 CD4 Driected Post-Attachment HIV Inhibitor
5:31 TMB-301 Study
8:45 TMB-301 Efficacy at Day 14
9:22 TMB-301 Efficacy at Week 25
10:43 TMB-301 Adverse Events
11:57 Resistance Testing and Cross Resistance
13:14 Summary
